Erlotinib loaded pegylated polypeptide lipid nanocapsules to enhance the anticancer efficacy in non-small cell lung cancer

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-FDP-016
• By: KIM, Jong Oh (Yeungnam University, Gyeongsan-si, Korea, Republic Of)
• Co-author(s): Jae Hee Kim: Yeungnam University, Gyeongsan-si, Korea, Republic Of
  Jun Ho Son: Yeungnam University, Gyeongsan-si, Korea, Republic Of
  Myung-Ja Hong: Yeungnam University, Gyeongsan-si, Korea, Republic Of
  Young-Im Lee: Yeungnam University, Gyeongsan-si, Korea, Republic Of
  Dong Shik Kim: Hanyang University, Ansan-si, Korea, Republic Of
  Han-Gon Choi: Hanyang University, Ansan-si, Korea, Republic Of
  Chul Soon Yong: Yeungnam University, Gyeongsan-si, Korea, Republic Of
  Jong Oh Kim: Yeungnam University, Gyeongsan-si, Korea, Republic Of
  
• Abstract:

  Background

  Lung cancer is the leading cause of cancer-related death worldwide. ERL blocks the kinase activity by selectively binding to the ATP-binding site of EGFR. The oral delivery of ERL is accompanied by severe side effects including rash, diarrhea, gastrointestinal (GI) perforations, ocular lesions, and hematological disorders. Therefore,..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login